Ongoing Trials in T-Cell Lymphomas

Video

Jasmine Zain, MD, from the Center for the Lymphoid Malignancies, Columbia University Medical Center, discusses two ongoing trials in T-cell lymphomas.

Jasmine Zain, MD, from the Center for the Lymphoid Malignancies, Columbia University Medical Center, discusses two ongoing trials in T-cell lymphomas.

Clinical Pearls:

  • Researchers are currently working on combining epigenetic therapies for the treatment of T-cell lymphomas
  • Vorinostat and romidepsin, which are the only two approved epigenetic therapies in this space, both have response rates close to 30%
  • Activity remains to be seen in a phase I trial looking at the combination of romidepsin and 5-azacytidine
  • Another trial is observing the activity of pralatrexate in combination with romidepsin
Related Videos
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Related Content